Cash from Operations (Quarterly) Chart

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
September 30, 2026 -32.71M
June 30, 2026 -37.24M
March 31, 2026 -32.96M
December 31, 2025 -30.94M
September 30, 2025 -26.96M
June 30, 2025 -34.71M
March 31, 2025 -32.64M
December 31, 2024 -39.70M
September 30, 2024 -44.04M
June 30, 2024 -35.14M
March 31, 2024 -51.97M
December 31, 2023 -40.60M
September 30, 2023 -38.66M
June 30, 2023 -79.28M
March 31, 2023 -49.28M
December 31, 2022 -37.33M
Date Value
September 30, 2022 -33.20M
June 30, 2022 -43.03M
March 31, 2022 -50.20M
December 31, 2021 -37.02M
September 30, 2021 -33.49M
June 30, 2021 -46.11M
March 31, 2021 -37.47M
December 31, 2020 -27.36M
September 30, 2020 -20.56M
June 30, 2020 -22.03M
March 31, 2020 -16.87M
December 31, 2019 -13.19M
September 30, 2019 -9.988M
June 30, 2019 -6.958M
March 31, 2019 -9.006M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
ARS Pharmaceuticals, Inc. -33.71M
ACADIA Pharmaceuticals, Inc. 11.50M
Alnylam Pharmaceuticals, Inc. 340.98M
Anika Therapeutics, Inc. 8.377M
Savara, Inc. -42.46M